Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Sep 30;12(9):2433-2437.
doi: 10.21037/tcr-23-726. Epub 2023 Aug 3.

PARP inhibition and immunotherapy: a promising duo in fighting cancer

Jordan Phillipps #  1 , Alice Y Zhou #  2 , Omar H Butt  2 , George Ansstas  2
Affiliations
Editorial

PARP inhibition and immunotherapy: a promising duo in fighting cancer

Jordan Phillipps et al. Transl Cancer Res. .
No abstract available

Keywords: Poly (adenosine diphosphate-ribose) polymerase inhibition (PARP inhibition); combinatory PARP inhibition and immunotherapy; immunotherapy; oncology; targeted and immune cancer therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-726/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Yap TA, Bardia A, Dvorkin M, et al. Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial. JAMA Oncol 2023;9:40-50. 10.1001/jamaoncol.2022.5228 - DOI - PMC - PubMed
    1. Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther 2021;6:254. 10.1038/s41392-021-00648-7 - DOI - PMC - PubMed
    1. Cai Z, Liu C, Chang C, et al. Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis. Pharmacol Res 2021;172:105808. 10.1016/j.phrs.2021.105808 - DOI - PubMed
    1. Cong K, Peng M, Kousholt AN, et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell 2021;81:3128-3144.e7. 10.1016/j.molcel.2021.06.011 - DOI - PMC - PubMed
    1. Li H, Liu ZY, Wu N, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 2020;19:107. 10.1186/s12943-020-01227-0 - DOI - PMC - PubMed

LinkOut - more resources